Aurinia v. DIFGEN: LUPKYNIS Generic Challenge Consolidated in NJ District Court
Aurinia Pharmaceuticals filed suit against DIFGEN Pharmaceuticals in the District of New Jersey, asserting two patents covering its voclosporin drug product LUPKYNIS against DIFGEN’s proposed generic versions. The court consolidated the related actions for all pre-trial purposes, a procedural step that signals multiple ANDA-related filings are being managed together before a single judge.
Aurinia’s LUPKYNIS patents face generic challenge at D.N.J.
Aurinia Pharmaceuticals, Inc. filed suit in the District of New Jersey on April 30, 2025, asserting US11622991B2 and US10286036B2 against DIFGEN Pharmaceuticals LLC in connection with DIFGEN’s proposed generic versions of LUPKYNIS (voclosporin), a calcineurin inhibitor approved for lupus nephritis. The case number is 2:25-cv-03533 and was assigned to the New Jersey District Court. Aurinia was represented by Gibbons PC, while DIFGEN retained Midlige Richter LLC.
On December 3, 2025 — 217 days after filing — the court issued an order consolidating the above-captioned actions for all pre-trial purposes, including discovery and case management, subject to further order of the court. The basis of termination recorded is ‘Case Consolidated,’ meaning this individual docket entry was closed as a distinct administrative matter, with proceedings continuing under the consolidated action. No merits ruling or settlement has been recorded at this stage.
The relatively swift consolidation order, issued within seven months of filing, is consistent with standard Hatch-Waxman case management practice in New Jersey, where related ANDA litigation filings against the same branded product are routinely consolidated to promote efficiency. What remains unknown from the public record is the full scope of ANDA filers implicated, the precise claim mapping of each asserted patent to DIFGEN’s proposed generic, and whether any 30-month stay has been triggered.
Filing to Case Consolidated in 217 days
217 days from filing to consolidation order — typical for early-stage Hatch-Waxman pre-trial management
Case consolidated: what the consolidation order means for both parties
Consolidation closes individual dockets, not the dispute
A ‘Case Consolidated’ termination means the court merged related parallel actions into a single docket for pre-trial management. The underlying patent infringement claims are not dismissed or resolved — they continue under the consolidated case number. This is a standard procedural tool in multi-ANDA Hatch-Waxman litigation, allowing one judge to manage overlapping discovery and scheduling without duplicative proceedings.
Procedural consolidationAurinia retains full enforcement posture for both patents
For Aurinia, consolidation is procedurally neutral on the merits. Both asserted patents — US11622991B2 and US10286036B2 — remain in force and asserted. Consolidation may actually benefit the patent holder by concentrating litigation costs and creating a unified discovery record against all generic challengers, strengthening Aurinia’s ability to enforce a consistent claim construction across the proceedings.
Patents remain assertedDIFGEN faces coordinated pre-trial proceedings under one judge
For DIFGEN, consolidation means its defense will proceed alongside any other ANDA filers challenging LUPKYNIS patents, under a single discovery schedule. This can reduce individual discovery leverage but also creates opportunities to share the burden of invalidity and non-infringement arguments with co-defendants, if any exist under the consolidated action.
Unified discovery scheduleConsolidated docket signals multiple generic challengers in the LUPKYNIS pipeline
Consolidation of multiple actions typically signals that more than one ANDA filer has notified Aurinia of a paragraph IV certification against its voclosporin patents. For the generic pharmaceutical sector, the outcome of this consolidated proceeding will set precedent on the validity and enforceability of Aurinia’s key LUPKYNIS IP, directly affecting generic market entry timing for voclosporin in the United States.
Generic market entry at stakeFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Aurinia Pharmaceuticals, Inc. | Company | Biopharmaceutical company — holder of US11622991B2 and US10286036B2 covering LUPKYNIS (voclosporin)Search in Eureka ↗ |
| Defendant | DIFGEN PHARMACEUTICALS LLC | Company | Generic pharmaceutical company challenging Aurinia’s voclosporin patents via proposed ANDA filingSearch in Eureka ↗ |
| Plaintiff counsel | C. COLLETTE CORSER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | DANIELLE A. DUSZCZYSZYN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMILY R. GABRANSKI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | EMMA CAPITANELLI | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | J. BRUGH LOWER | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | JUSTIN SILVERBERG | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | MARK FELDSTEIN | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | RYAN V. MCDONNELL | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | William P. Deni , Jr. | Attorney | Counsel for Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Aurinia Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for DIFGEN PHARMACEUTICALS LLCSearch in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing DIFGEN PHARMACEUTICALS LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order is purely procedural: the court directed that the captioned actions be merged for pre-trial purposes including discovery and case management. No infringement finding, validity ruling, or damages determination has been made. The phrase ‘subject to further order of the Court’ preserves judicial discretion to de-consolidate or modify the arrangement. For both parties, the substantive dispute over US11622991B2 and US10286036B2 remains entirely open.
US11622991B2 & US10286036B2 — voclosporin (LUPKYNIS) drug patents
US11622991B2 (application US17/713140) and US10286036B2 (application US15/835219) both relate to voclosporin, a next-generation calcineurin inhibitor marketed by Aurinia as LUPKYNIS for the treatment of lupus nephritis. Calcineurin inhibitors suppress T-cell-mediated immune responses, and voclosporin’s structural modification over cyclosporine is designed to improve the therapeutic index. The two patents likely cover distinct aspects of the compound’s formulation, dosing regimen, or therapeutic use, providing overlapping protection around the LUPKYNIS franchise.
For the specialty pharmaceutical sector, these patents represent the primary IP barrier to generic voclosporin entry. LUPKYNIS was the first FDA-approved oral therapy specifically indicated for lupus nephritis, a high-unmet-need indication. Any generic pharmaceutical company seeking ANDA approval must either design around both patents, challenge their validity under paragraphs II–IV of the Hatch-Waxman Act, or wait for expiry. With two patents in suit asserting separate application lineages, the challenge for ANDA filers is materially elevated.
Should your team run an FTO against US11622991B2 and US10286036B2?
Any company developing a generic or biosimilar voclosporin product, or any calcineurin inhibitor formulation for autoimmune nephrology indications, should assess freedom-to-operate against both US11622991B2 and US10286036B2 before progressing to ANDA filing or clinical development. The breadth of claims in these patents — and the fact that Aurinia is actively enforcing both — means that a standard prior art search is insufficient; a full claim mapping against your proposed formulation and method of use is required.
PatSnap Eureka’s FTO Search Agent can rapidly map the independent and dependent claims of both asserted patents against your product specification, flag design-around opportunities, and identify prior art relevant to validity challenges. Eureka’s AI-powered claim analysis surfaces the prosecution history of both application lineages — including any claim amendments that may narrow or broaden the scope of enforceability — giving your IP and R&D teams the intelligence needed to assess litigation risk before entering the voclosporin generic market.
Run a freedom-to-operate analysis on US11622991B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA patent cases: calcineurin inhibitor and lupus nephritis litigation
Explore comparable Hatch-Waxman infringement cases involving calcineurin inhibitor and specialty renal/autoimmune drug patents filed in the District of New Jersey.
What this case signals for the branded generic pharma IP landscape
The LUPKYNIS consolidation reflects broader Hatch-Waxman enforcement dynamics in New Jersey — the default venue for major ANDA patent battles.
New Jersey remains the epicentre of Hatch-Waxman patent enforcement
The District of New Jersey is the busiest venue for ANDA-related patent litigation in the US. Aurinia’s choice to file there, and the court’s rapid consolidation order, is consistent with the court’s developed expertise in managing complex multi-party pharmaceutical patent disputes. Companies monitoring LUPKYNIS generic entry should track the consolidated docket closely.
Two-patent assertion strategy suggests layered voclosporin IP protection
Asserting both US11622991B2 and US10286036B2 — with distinct application numbers and likely different claim scopes — suggests Aurinia has constructed overlapping patent protection around voclosporin. This layered strategy increases the burden on any ANDA filer to design around or invalidate multiple independent claim sets before generic entry becomes commercially viable.
Aurinia v DIFGEN — key questions answered
In Aurinia v. DIFGEN, ‘Case Consolidated’ means the court merged this and related actions into a single docket for all pre-trial purposes including discovery and case management. The underlying patent infringement claims over US11622991B2 and US10286036B2 remain active and unresolved — consolidation is a procedural step, not a merits ruling.
Aurinia asserted two patents: US11622991B2 (application US17/713140) and US10286036B2 (application US15/835219). Both relate to voclosporin, marketed as LUPKYNIS, approved for lupus nephritis. The case involves DIFGEN’s proposed generic versions of the LUPKYNIS drug product.
The public record of case 2:25-cv-03533 does not explicitly confirm a 30-month stay, but if Aurinia filed suit within 45 days of receiving DIFGEN’s paragraph IV certification notice, a statutory 30-month stay on FDA approval of DIFGEN’s ANDA would be automatically triggered under 21 U.S.C. § 355(j)(5)(B)(iii). Given the April 2025 filing date, any stay would tentatively run to late 2027 or early 2028.
LUPKYNIS (voclosporin) is a calcineurin inhibitor developed by Aurinia Pharmaceuticals and approved by the FDA as the first oral therapy specifically indicated for lupus nephritis. Its commercial success and high-unmet-need indication make it an attractive target for ANDA filers seeking generic market entry. Patent litigation is a standard mechanism under the Hatch-Waxman Act for brand holders to defend exclusivity periods.
Aurinia Pharmaceuticals is represented by Gibbons PC, with a team including William P. Deni Jr., J. Brugh Lower, Mark Feldstein, Ryan V. McDonnell, and others. DIFGEN Pharmaceuticals is represented by Midlige Richter LLC, with James S. Richter listed as defendant’s agent. The case is pending in the District of New Jersey.
PatSnap Eureka searches patents and litigation data to answer instantly.